Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Board Changes

26 Mar 2013 16:19

RNS Number : 9352A
Plant Health Care PLC
26 March 2013
 



 

26 March 2013

 

Plant Health Care plc

("Plant Health Care" or "the Company")

Board Changes 

Plant Health Care plc, ("PHC"),a leading provider of novel patent protected biological products to the global agriculture markets, is today announcing the appointment of a new Chief Executive Officer, among other Board changes.

 

After twelve years as CEO of Plant Health Care, John Brady will be stepping down on 2 April 2013. He will be succeeded by Paul Schmidt who will take over as CEO the same day.

 

John has provided outstanding leadership of the Company and the Board would like to pay tribute to his enormous contribution. The Board is delighted that the Company is retaining John's services as a non-executive director, in which role the Company will continue to benefit from his invaluable experience.

 

The Company is pleased to welcome Paul Schmidt. Mr Schmidt has extensive operational experience in the agriculture industry, having served in senior roles in the USA, Germany and Canada during 25 years with Bayer CropScience and its predecessor companies. As President of Merck/EMD Crop Bioscience, a leading developer of natural plant health products, Paul led a turn-around which resulted in substantially increased sales and profit. In February 2011, he oversaw the sale of the business to Novozymes for $275 million. Paul graduated from the University of Saskatchewan with a BSA in Agronomy in 1980.

 

Sam Wauchope, having served as a non-executive director for nine years, four of them as Senior Independent Director, will step down from the Board on 2 April 2013. The Board would like to thank Sam for the contribution he has made to the Company.

 

Michael Higgins will join the Company as the Senior Independent Director and Chair of the Audit Committee following the Company's AGM on 9 May 2013. He is currently non-executive Chairman of AIM quoted Ebiquity plc and Deputy Chairman of the Quoted Companies Alliance. Michael also works with, and invests in, a number of early-stage businesses. Michael was a Senior Adviser at KPMG following ten years as a Partner. Prior to KPMG, he was a Director at Charterhouse Bank, worked at Saudi International Bank and qualified as an accountant with Price Waterhouse (now PricewaterhouseCoopers).

 

Dr. Christopher Richards, Chairman commented: "I wish to place on record our appreciation of all that John has done for Plant Health Care; this Company is very much his personal creation. I am delighted that we are retaining John's services as a non-executive director, in which role we will continue to benefit from his invaluable experience. I would also like to take this opportunity to pay tribute to Sam for his contribution, which included a stint as Interim Chairman in 2012.

 

"Securing the services of Paul Schmidt as the Company's new CEO is a real coup. Paul's extensive experience in the industry leaves us very well positioned to progress to the next stage in the Company's development. I am convinced that Paul has the right qualities to lead Plant Health Care to this next level. We look forward to welcoming Michael to the Company and to the Board following our AGM. Michael will bring a wealth of additional experience that we will benefit from."

 

 

- ENDS -

 

About Plant Health Care plc: Plant Health Care plc ("Plant Health Care") is a leading provider of novel patent protected biological products to the global agriculture markets. The Company's ordinary shares have been quoted on the AIM Market of the London Stock Exchange since July 2004 and listed on the Official List of the Channel Islands Stock Exchange ("CISX") since February 2010 (ticker symbol/mnemonic: PHC).

Further information is available at: www.planthealthcare.com.

 

 For further information, please contact:

Plant Health Care plc

 

 

Dr Christopher Richards, Chairman

On the day Tel: +44 (0) 20 7250 1446

John Brady, Chief Executive Officer

On the day Tel: +44 (0) 20 7250 1446

Thereafter: Tel: +1-603-525-3702 

Stephen Weaver, Finance Director

Tel: +1-412-826-5488 x151

 

Nomura Code Securities

Chris Collins / Clare Terlouw / Chris Golden

Tel: +44 (0) 20 7776 1200

Powerscourt

Paul Durman / Nick Dibden / Sophie Moate

Tel: +44 (0) 20 7250 1446

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAJFMFTMBBTBJJ
Date   Source Headline
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options
2nd Jun 202011:13 amRNSResult of AGM
29th May 20207:00 amRNSHolding(s) in Company
27th May 20207:00 amRNSUpdate on PHC279 2019 Field Trials
6th May 20205:12 pmRNSAnnual Report & Accounts and AGM Notice Published
1st May 20203:21 pmRNSDirector/PDMR Shareholding
24th Apr 20207:00 amRNSResults for the year ended 31 December 2019
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20203:45 pmRNSHolding(s) in Company
19th Mar 20203:09 pmRNSHolding(s) in Company
16th Mar 202011:53 amRNSResults of General Meeting
11th Mar 20207:00 amRNSPHC279 Submitted for Regulatory Approval in Brazil
24th Feb 20209:18 amRNSResults of Placing and Subscription
24th Feb 20207:00 amRNSProposed Placing and Subscription
19th Feb 20207:00 amRNSBlock listing Interim Review
5th Feb 20207:00 amRNSEmploy California Registration
23rd Jan 20207:00 amRNSFirst US patent issues for PREtec peptide products
9th Jan 20207:00 amRNSBrazil Update
20th Dec 20197:00 amRNSHolding(s) in Company
19th Dec 20197:00 amRNSTrading Update
3rd Dec 20196:35 pmRNSHolding(s) in Company
22nd Nov 20192:11 pmRNSHolding(s) in Company
15th Nov 20193:42 pmRNSHolding(s) in Company
15th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20193:36 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSHolding(s) in Company
13th Nov 20194:40 pmRNSHolding(s) in Company
13th Nov 20194:08 pmRNSHolding(s) in Company
13th Nov 20193:59 pmRNSHolding(s) in Company
13th Nov 20193:42 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.